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ABSTRACT
Overexpression of the anti-apoptotic protein BCL-2 is characteristic of human 
follicular lymphoma (FL) and some cases of diffuse large B cell lymphoma (DLBCL). We 
aimed to determine autophagy status in primary FL and DLBCL samples and the BCL-
2+/BCL-2- lymphoma cell lines using both autophagy PCR array and tissue microarray 
(TMA). A greater number of autophagy machinery genes were up-regulated in the 
BCL-2+ Su-DHL4 cell line compared with BCL-2- Su-DHL8 cells, at both the basal level 
and in response to autophagic stress. The autophagy-related gene expression profiles 
were determined in purified and unpurified malignant human lymph node biopsies. 
Seven autophagy machinery genes were up-regulated in purified FL B-cells compared 
with reactive B-cells. Only 2 autophagy machinery genes were up-regulated in DLBCL 
B-cells. In unpurified tissue biopsies, 20 of 46 genes in FL and 2 of 5 genes in DLBCL 
with increased expression were autophagy machinery genes. Expression of autophagy 
substrates p62 and LC3 were determined by TMAs. FL samples showed significantly 
decreased levels of both p62 and LC3 compared with reactive and DLBCL, indicative 
of an increased autophagy activity in FL. In summary, these results demonstrate that 
FL showed increased basal autophagy activity, regardless of overexpression of BCL-2 
in this disease. 
INTRODUCTION
Macroautophagy (hereafter referred to as 
autophagy) is a physical and pathological process that 
allows eukaryotic cells sequester portions of cytoplasm 
to form autophagosomes and target them for degradation 
through the fusion of autophagosomes with lysosomes 
where they are degraded and recycled [1-4]. Growing 
evidence demonstrates that autophagy plays important and 
paradoxical roles in tumorigenesis and in the treatment of 
cancer [4-7]. Autophagy can suppress tumorigenesis by 
removing damaged organelles/proteins and limiting cell 
growth and genomic instability [6]. In contrast, induction 
of autophagy by metabolic stress in apoptosis deficient 
tumor cells can support tumor cell survival [8]. Abundant 
preclinical evidence indicates that stress-induced 
autophagy in tumor cells is predominantly cytoprotective 
and inhibition of autophagy can enhance tumor cell death 
by diverse anticancer therapies [9-11]. 
Follicular lymphoma (FL) is the second most 
common lymphoma diagnosed in the United States and 
Western Europe, accounting for approximately 20% of all 
non-Hodgkin lymphomas (NHLs) and 70% of indolent 
lymphomas and is generally considered incurable [12, 
13]. The t(14;18)(q32;q21) translocation characterizes 
approximately 85% of FL and 20% of diffuse large 
B-cell lymphoma (DLBCL) and results in constitutive 
overexpression of the anti-apoptotic protein BCL-2 [14, 
15]. Overexpression of BCL-2 in NHLs plays important 
roles in disease pathogenesis and resistance to apoptosis. 
It is currently unknown whether BCL-2 plays an important 
role in regulation of autophagy in indolent FL and more 
aggressive DLBCL. 
The role of the anti-apoptotic protein BCL-2 in 
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autophagy is currently debated and remains unclear. 
BCL-2 has been proposed as a major binding partner of 
Beclin-1 which it binds in a nutrient-dependent manner, 
consequently down-regulating levels of starvation-
mediated autophagy [16]. Recently, it was reported that 
the anti-apoptotic BCL-2 family members do not directly 
inhibit components of the autophagic pathway but instead 
affect autophagy indirectly, owing to their inhibition of 
Bax and Bak [17]. Autophagy is often activated as an 
adaptive response against ER stress [18, 19]. In cancer 
cells, metabolic stress strongly induces autophagy which is 
sustained when apoptosis is blocked [8, 20, 21]. Questions 
raised over the roles of BCL-2 in autophagy are: whether 
overexpression of BCL-2 in human tumors inhibits both 
apoptosis and autophagy; and whether inhibition of 
apoptosis by overexpression of BCL-2 could activate 
the autophagic pathway in favor of prolonged tumor cell 
survival. 
The role of BCL-2 in autophagy in human NHLs 
has not previously been reported. We hypothesize that 
overexpression of BCL-2 in FL may cause an increased 
autophagy activity due to suppression of apoptosis. In this 
article, we aimed to determine whether overexpression 
of BCL-2 could alter autophagy status in BCL-2 positive 
(BCL-2+) and negative (BCL-2-) DLBCL cell lines, 
primary FL, DLBCL and reactive (RA) samples using 
both autophagy RT2 Profiler PCR Array and tissue 
microarray (TMA). We demonstrate for the first time that 
overexpression of BCL-2 does not inhibit autophagy in 
human FL. 
RESULTS
BCL-2+ DLBCL cells showed an increased basal 
autophagy activity
To evaluate the impact of BCL-2 overexpression 
on autophagy in human lymphoma, we first compared the 
autophagy status of the BCL-2+ Su-DHL4 with the BCL-
2- Su-DHL8 DLBCL cell lines using Western blotting and 
the RT2 Profiler PCR array (Figure 1). Overexpression 
of BCL-2 in Su-DHL4 cells was confirmed by Western 
blotting and there was no differential expression of 
Beclin-1 or Bcl-xL, another binding partner of Beclin-1, 
between these two cell lines. SQSTM1/p62 (p62) serves 
as a link between LC3 and ubiquitinated substrates 
resulting in these two proteins being incorporated into 
the completed autophagosome and degraded in the 
autolysosome [22, 23]. Both p62 and LC3-II showed 
increased expression in the Su-DHL8 cell line (Figure 1 
A), indicative of inhibited autophagic degradation [24], 
suggesting that the autophagy flux may be inactive in this 
BCL-2- cell line compared with the BCL-2+ Su-DHL4 
cells. Using autophagy PCR array, we detected that the Su-
DHL4 cell line was also distinguishable from Su-DHL8 
cells based on its autophagy-related gene expression 
profile (GEP) (Figure 1 B and Suppl Figure 1). Four 
autophagy machinery and nine autophagy regulatory genes 
were up-regulated in the Su-DHL4 cell line compared to 
Su-DHL8 cells (Figure 1 C and D). These data support 
that BCL-2+ Su-DHL4 cells may have higher basal level 
autophagy activity compared with BCL-2- Su-DHL8 cells. 
We next sought to determine the capacity of 
the autophagic flux in both BCL-2+ and BCL-2- cells. 
Inhibition of the autophagic flux by treatment of cells 
with CQ [7, 25] or induction of autophagy by nutrient 
deprivation led to increased or decreased p62 and LC3B-I/
LC3B-II protein expression respectively in both cell 
lines (Figure 2 A and B), demonstrating that autophagy 
activity was not suppressed in the BCL-2+ Su-DHL4 cells. 
Beclin-1 expression did not change in response to either 
treatment, indicating that its levels are not governed by 
the autophagy flux. Both Su-DHL4 (Figure 2 C and E 
and Suppl Figure 2) and Su-DHL8 (Figure 2 D and F and 
Suppl Figure 3) cell lines responded to nutrient deprivation 
by up-regulating and down-regulating autophagy-related 
genes. Among them, SQSTM1 (p62) and CDKN1B genes 
showed significantly increased expression in both cell 
lines (Figure 2 E and F). Between 2 and 6 hours starvation, 
we also noted increased p62 protein expression despite 
increased autophagic degradation (Figure 2 B). A similar 
phenomenon has also been observed in mouse embryonic 
fibroblasts [26]. Increased expression of CDKN1B in 
response to starvation may cause cell cycle arrest in 
the G1 phase [27]. In addition, the Su-DHL4 cell line 
also showed significantly increased expression of key 
autophagy machinery genes including GABARAPL1, 
GABARAPL2, MAP1LC3B (LC3B) and CTSS (Figure 2 C 
and E). These results suggest that BCL-2+ cells may have 
increased autophagy activity in response to autophagy 
stress compared with BCL-2- cells. 
FL B-cells showed an increased expression of 
autophagy-related genes
We next evaluated autophagy gene expression levels 
in primary FL and DLBCL samples and compared them to 
RA controls. In order to differentiate autophagy activity in 
lymphoma B-cells from surrounding stromal cells, tumor-
infiltrating T-cells and macrophages, B-cell subsets were 
isolated by flow cytometry. CD3+ T-cells were excluded 
and CD10+/CD19+ B-cells (FL) and CD20+ B-cells 
(DLBCL and RA) were purified from primary single cell 
suspensions. B-cell receptor (BCR) isotype restriction 
is a hallmark of FL cells, and purified CD19+/CD10+ FL 
B-cells were found to be either κ or λ light-chain restricted 
(Figure 3 A). After flow sorting, mean purities of B-cells 
were ≥95% for all samples. 
We analyzed the autophagy-related GEP of highly 
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Table 1: Aberrantly expressed autophagy-related genes in purified and unpurified FL and DLBCL samples.
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purified and unpurified FL and DLBCL diagnostic 
tissue biopsies and compared them with non-malignant 
RA samples. The results of unsupervised hierarchical 
clustering are shown for purified reactive and malignant 
B-cells (Figure 3 B) and unpurified tissue biopsies 
(Figure 3 C). Seven and two autophagy machinery genes 
were up-regulated in purified FL and DLBCL samples, 
respectively (Table 1), one of which, MAP1LC3A was 
commonly up-regulated in both FL and DLBCL purified 
B-cells. Only one gene, BNIP3, showed significantly 
decreased expression in both FL and DLBCL B-cells. 
BNIP3 is a hypoxia-dependent autophagy inducer and 
its expression is suppressed in many types of cancer [28] 
but overexpressed in lung and breast carcinomas [29]. 
Gene expression patterns in both FL and DLBCL were 
not associated with Ann Arbor stage or international 
prognostic index (IPI) scores (data not shown). Among 
the 46 genes which showed increased expression in 
these samples, 19 genes in FL and 2 genes in DLBCL 
were autophagy machinery genes (Figure 3 C and Table 
1) and 27 genes in FL and 3 in DLBCL were autophagy 
regulatory genes. Both BECN1 and BCL2 genes were 
up-regulated in FL but not in DLBCL tissue biopsies. 
Expression of two lysosomal components CTSD 
(cathepsin D) and DRAM1 (damage-regulated autophagy 
modulator 1) [30] was significantly up-regulated in both 
FL and DLBCL tissue biopsies, suggesting they may be 
expressed at higher levels in the tumor microenvironment. 
CDKN2A (p16), a tumor-suppressor gene, is up-regulated 
in both purified and unpurified FL and DLBCL samples 
(Table 1). To consolidate these findings, increased 
expression of BECN, MAP1LC3A, ATG4B, DRAM1 and 
CTSD was validated in unpurified tissue using qRT-PCR. 
Results were comparable to those obtained from the PCR 
array (Suppl Table 8). These data demonstrate that both 
FL and DLBCL samples aberrantly express autophagy 
genes at the basal levels. In particular, FL samples which 
frequently overexpress BCL-2 have increased expression 
of numerous autophagy machinery and regulatory genes. 
In the cohort of purified samples, two FL patients 
(T1979 and T5728) with high global expression of 
autophagy genes subsequently underwent transformation 
to the more aggressive DLBCL later in their clinical 
course (Suppl Figure 4 A and Suppl Table 1). In unpurified 
tissue biopsies, 7 of 8 FL and 1 of 10 DLBCL samples 
showed increased global expression of autophagy genes 
compared to RA tissues (Suppl Figure 4 B). A larger 
number of purified DLBCL samples will be required to 
establish aberrant expression of autophagy genes in this 
disease. 
FL showed significantly decreased expression of 
autophagy substrates p62 and LC3 proteins
To establish the autophagy status of FL and DLBCL, 
primary FL, DLBCL and RA LN tissue biopsies on TMAs 
were stained using IHC for the autophagy substrate 
Fold changes (F.C.) in gene expression levels of unpurified (UP) FL or DLBCL samples were compared with unpurified 
RA-LNs and those of purified (P) FL or DLBCL samples were compared with purified reactive B cells. Genes listed in 
the table are genes with expression changes greater than or less than 3 fold and those greater than or less than 2 fold with 
a P value <0.05. Numbers of samples: purified RA n=3; FL n=5; DLBCL n=2; unpurified RA n=8; FL=8; DLBCL n=10. 
Significantly increased or decreased fold changes were identified using a Mann Whitney U test. Numbers in the first column 
indicate the functions of these genes, according to the classification of human autophagy PCR array (Sabiosciences): (1-6) 
Autophagy machinery genes: (1) Genes involved in autophagic vacuole formation; (2) Gene responsible for protein targeting 
to membrane/vacuole; (3) Genes responsible for protein transport; (4) Genes linking autophagosome to lysosome; (5) Genes 
involved in protein ubiquitination;  (6) Genes with protease activity; (7-10) Autophagy regulatory genes: (7) Co-regulators 
of autophagy and apoptosis; (8) Co-regulators of autophagy and the cell cycle; (9) Autophagy induction by intracellular 
pathogens; (10) Autophagy in responsible to other intracellular signals. 
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proteins p62 and LC3, and autophagy initiating protein 
Beclin-1 (Figure 4A). RA and FL samples were stained 
with CD10 antibody to distinguish follicular center B-cells 
from surrounding cells. CD10+ area were classified as 
intra-follicular areas; CD10- areas were classified as inter-
follicular areas [31] (Suppl Figure 5A). 
First, protein expression in FL intra-follicular areas 
was compared with RA and DLBCL whole core samples. 
p62, LC3 and Beclin-1 showed significantly decreased 
expression in FL intra-follicular areas compared with 
DLBCL and RA controls. Only Beclin-1 displayed 
significantly decreased expression in DLBCL (Figure 
4 B, D and F). Most strikingly, all FL samples showed 
consistently lower levels of p62. Expression of p62 
in DLBCL and LC3 and Beclin-1 in FL and DLBCL 
displayed a heterogeneous expression pattern. In FL, 
significantly decreased expression of p62, LC3 and 
Beclin-1 was observed in both intra-follicular and non-
malignant inter-follicular areas (Figure 4 C, E and G), 
suggesting autophagy may be altered in both malignant 
FL cells and surrounding tumor infiltrating cells. 
Approximately 91% FL samples were BCL-2 positive 
Figure 1: Determination of basal autophagy status in BCL-2+ Su-DHL4 and BCL-2- Su-DHL8 cell lines. (A) Comparison 
of autophagy-related protein expression by Western blotting. 50 µg proteins were loaded onto each lane of a 12-well SDS-PAGE gel. 
Proteins were transferred to a PVDF membrane which was probed with primary antibody at 4°C overnight. Primary antibodies were used at 
a 1:2000 dilution for GAPDH and at 1:1000 for all other antibodies. Levels of protein expression were measured by densitometry. Numbers 
below panels of Western blots indicate the ratio of a specific protein to GAPDH. (B) Supervised hierarchical clustering of significantly 
differentially expressed autophagy machinery and autophagy regulation genes. Heat-map shows triplicate RQ values for Su-DHL4 and Su-
DHL8 cell lines. Each column represents an mRNA/RQ value and each row a gene. Gene expression levels are represented as a gradient of 
blue to red color indicating low and high expression respectively. Side bars were removed for clarity. (C and D) RQ values of significantly 
increased or decreased autophagy machinery (C) and autophagy regulatory (D) genes differentially expressed in the Su-DHL4 cell line 
compared with the Su-DHL8 cell line, analyzed using student t-test (P<0.05) and represented as fold changes. 
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Figure 2: Inhibition or induction of the autophagic flux in Su-DHL4 and Su-DHL8 cell lines. (A) Blocking autophagic 
flux. Cells were incubated in normal culture medium in the presence or absence of 50 µM CQ. (B) Induction of autophagy by starvation. 
Cells were incubated in HBSS for up to 6 hours. Cells were collected at each indicated time point for protein extraction and Western 
blotting. Numbers below each band indicate ratios of specific proteins to GAPDH which were determined by densitometry. (C and D) 
Supervised hierarchical clustering of significantly differentially expressed autophagy related genes in Su-DHL4 (C) and Su-DHL8 (D) 
cells after incubation in HBSS for 6 hours. Heat-map shows triplicate RQ values for normal and HBSS cultured Su-DHL4 and Su-DHL8 
cell lines. Each column represents an mRNA/RQ value and each row a gene. Gene expression levels are represented as a gradient of blue 
to red color indicating low and high expression respectively. (E and F) RQ values of autophagy related genes significantly differentially 
expressed in Su-DHL4 (E) and Su-DHL8 (F) cells after incubation in HBSS for 6 hours were analyzed by the paired student t-test (p<0.05) 
and represented as fold changes. Red bars indicate changes in autophagy machinery genes and black and white bars indicate changes in 
autophagy regulatory genes.
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Figure 3: Determination of expression of autophagy related genes in purified and unpurified FL and DLBCL samples. 
(A) Flow sorting of B-cells. Immunophenotyping was used to isolate the B-cell population from human RA, FL and DLBCL single cell 
suspensions. B-cells were identified as CD3- CD20+ for RA and DLBCL samples and CD3-/CD10+/CD19+ for FL samples. Purified FL 
B-cells were confirmed as being either κ or λ light chain restricted. (B and C) Unsupervised hierarchical clustering using autophagy-related 
genes expressed in purified B cells (B) and unpurified bulk biopsies (C). Five FL, 2 DLBCL and 3 RA purified samples (B) and 8 FL, 10 
DLBCL and 8 RA tissue biopsies (C) were analyzed by qRT-PCR. Heat-map shows RQ values where each column represents a patient and 
each row a gene. Gene expression levels are represented as a gradient of blue to red color indicating low and high expression respectively; 
gray indicates missing data. 
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(>30% of stained area); DLBCL samples displayed 
a heterogeneous BCL-2 expression pattern (Suppl 
Figure 5 B and C). These results demonstrate that FL 
has an increased basal autophagy activity, regardless of 
overexpression of BCL-2. 
In order to understand the association between 
BCL-2 and p62, LC3 or Beclin-1, correlations between 
these proteins in RA, FL and DLBCL were analyzed by 
Pearson product-moment correlation method (Figure 5). 
BCL-2 levels showed a negative correlation with p62 in 
FL (P<0.05) and positive correlation with p62, LC3 or 
Beclin-1 in DLBCL (P<0.01), suggesting that BCL-2 
does not play a dominant role in autophagy status in these 
lymphomas. Expression levels of p62 and LC3 showed 
strong positive correlation (P<0.0001) in RA, FL and 
DLBCL samples, indicating that p62 or LC3, individually 
or in combination, can be used as a marker for evaluating 
autophagy activity. Interestingly, Beclin-1 expression 
Figure 4: Comparison of p62, LC3 and Beclin-1 protein expression in FL and DLBCL with RA-LN. (A) Representative 
histochemical stained images of p62, LC3, and Beclin-1 in RA, FL and DLBCL. Proteins were stained with polyclonal anti-p62, polyclonal 
anti-LC3B antibody, or a mouse anti-Beclin-1 antibody respectively. Detailed information of antibodies and their dilution are listed in 
the Suppl Table 5. Red arrows indicate positive cells. (B-G) Statistical analysis p62 (B and C), LC3B (D and E) and Beclin-1 (F and G) 
expression. All data presented are medians with interquartile ranges. Sample numbers for RA and FL in C, E and G are as same as listed in 
B, D and F. Statistical difference between samples was analyzed by unpaired Mann-Whitney U test. *P<0.05, **P<0.01, and ***P<0.0001. 
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levels were positively correlated with levels of p62 and 
LC3 in both FL (P<0.01) and DLBCL (P <0.0001), 
suggesting that Beclin-1 levels is not positively associated 
with autophagy activity. 
Cathepsin D and tissue transglutaminase-2 are 
highly expressed in the tissue macrophages
Gene expression profiling of DLBCL malignant 
B-cells may be affected by the presence of stromal cells 
[32]. CTSD showed significantly increased expression 
at the gene level in FL and DLBCL sample biopsies but 
not in purified B-cells. Increased expression of TGM2 
(Tissue transglutaminase-2) was detected in both purified 
and unpurified DLBCL samples (Table 1). To distinguish 
the origins of these components, we evaluated expression 
of cathepsin D and TGM2 proteins in previously un-
treated FL, DLBCL and RA tissue biopsies and the 
results were reviewed by expert histopathologist (MC and 
RC). The expression pattern of cathepsin D and TGM2 
suggested that they are not expressed by lymphoma cells, 
but rather macrophages (Figure 5 A). To confirm cells 
highly expressing cathepsin D and/or TGM2 are tumor 
infiltrating cells, DLBCL and RA TMAs were stained 
with CD68, a marker for tumor-associated macrophages 
(TAMs) [33, 34] (Figure 5 B). These data confirmed that 
cells expressing cathepsin D and/or TGM2 are indeed 
macrophages, although co-localization between these 
proteins and CD68 was not evaluated. Cathepsin D 
expression was significantly lower in FL but significantly 
higher in DLBCL samples compared with RA controls 
(Figure 5 C), while both FL and DLBCL samples showed 
decreased expression of TGM2 (Figure 5 D). Neither 
Figure 5: Multiple analysis of correlation between BCL-2, p62, LC3 and Beclin-1. (A) RA; (B) FL and (C) DLBCL. 
Correlation was analyzed by Pearson product-moment correlation coefficient test. ‘γ’ indicates correlation coefficient. Sample numbers, 
RA=30; FL=50 and DLBCL=109.
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cathepsin D nor TGM2 expression was correlated with 
autophagy status in FL or DLBCL (data not shown). 
Both cathepsin D and TGM2 showed strong positive 
correlation (P<0.0001) with CD68 (Supp Figure 6 A 
and B). Expression of cathepsin D and TGM2 were also 
strongly correlated (P<0.0001) (Supp Figure 6 C). These 
results suggest that higher expression of autophagy 
genes in TAMs may lead to misinterpretation of the gene 
signature of malignant B-cells when analyzing autophagy 
in unpurified tissue biopsies by PCR array. 
DISCUSSION
Here we report that FL, an indolent NHL which 
frequently overexpresses the anti-apoptotic protein 
BCL-2, showed significantly increased expression of 
Figure 6: Immuno-histochemical staining of cathepsin D, TGM2 and CD68. (A) Representative images of cathepsin D and 
TGM2 expression in RA, FL and DLBCL. (B) Representative images of CD68 expression in RA and DLBCL. Antibody dilutions were 
1:1000, 1:750, or 1:8000 for anti-cathepsin D, anti-TGM2, or anti-CD68 antibodies, respectively. Images were taken with a Leixa DM2500 
microscope: original magnification X200. Cathepsin D, TGM2 and CD68 protein expression levels were defined as % stained viable tissue 
area. (C and D) Statistical analysis of protein levels of cathepsin D (B) and TGM2 (C) were calculated as the percent stained area of viable 
tissue. Data collected for RA and DLBCL were from whole cores and for FL were from the CD10+ intra-follicular area. Significantly 
increased or decreased expression between samples was analyzed by the Mann-Whitney U test. Numbers of samples used for analysis were 
indicated.
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key autophagy genes and decreased levels of autophagy 
substrate protein p62 and LC3 compared with RA B-cell 
controls. Whereas, the autophagy-related GEP and levels 
of autophagy substrate p62 and LC3 proteins in DLBCL, 
an aggressive NHL, was more similar to those of RA 
B-cell controls. A constitutive basal level of autophagy 
in normal tissue provides an important homeostatic, 
housekeeping function to survive stress, such as nutrient 
deprivation [21, 35]. The role of autophagy in cancer is 
complex as it can prevent tumor initiation by suppressing 
chronic tissue damage, inflammation, and genome 
instability via its quality control function or it can sustain 
tumor metabolism, growth, and survival via nutrient 
recycling [36], suggesting a link between dysregulated 
autophagy and tumor progression. 
Higher expression of the anti-apoptotic protein 
BCL-2 is more common in B-cell NHL than T-cell NHL 
and is heterogeneously expressed among the different 
histological subtypes [37]. Although BCL-2 is a well-
established anti-apoptotic protein, it was also proposed 
to suppress autophagy by binding and inhibiting Beclin-1 
in a cardiac BCL-2 transgenic mice model [16]. A recent 
finding demonstrated that BCL-2 does not bind directly to 
Beclin-1 but instead regulate autophagy by inhibiting Bax/
Bak mediated apoptosis [17]. We therefore determined 
the role of BCL-2 on autophagy in BCL-2+ and BCL-
2- cell lines and human primary lymphoma samples. 
Higher levels of autophagy machinery genes were found 
in BCL-2+ cells compared with the BCL-2- cell line. 
BCL-2+ and BCL-2- DLBCL cell lines showed similar 
autophagy flux activity upon either autophagy inhibition 
by CQ or autophagy induction by nutrient-deprivation, 
evidenced by accumulation or degradation of p62 and LC3 
proteins, respectively. Interestingly, the BCL-2+ cell line 
up-regulated more autophagy-related genes in response 
to starvation compared to BCL-2- DLBCL cells. These 
results demonstrate that the autophagic flux is not altered 
by the BCL-2 protein in human malignant B-cells. In fact, 
BCL-2+ cells up-regulate more autophagy-related genes 
than BCL-2- DLBCL cells in both the resting state and in 
response to autophagy induction.
As expected, the BCL-2 gene was highly expressed 
in both purified FL B-cells and unpurified tissue biopsies 
compared with RA and DLBCL primary samples. To 
identify expression signatures of autophagy-associated 
genes in the malignant population specifically, B-cells 
were purified from FL and DLBCL tissue biopsies by 
flow sorting. Normal B-cells were also purified from 
RA-LNs which served as controls. Seven autophagy 
machinery genes were up-regulated in purified FL B-cells, 
including ATG9A, ATG16L1, MAP1LC3A, GABARAPL1 
and ULK1, which are involved in autophagosome 
formation and protein transport; LAMP1, involved in 
autolysosome formation; and HDAC6, involved in protein 
ubiquitination. This result demonstrates that FL B-cells, 
which overexpress BCL-2 up-regulate the basal autophagy 
activity at the gene level. We have also confirmed by 
decreased expression of autophagy substrate proteins p62 
and LC3 in FL tissue specimens using TMAs and IHC, 
demonstrating an active autophagy at the protein levels in 
FL. Nevertheless, there is no strong and clear correlation 
between BCL-2 expression levels and autophagy activity. 
We therefore propose that autophagy activity in lymphoma 
samples may not be controlled by BCL-2.
FL frequently transforms to the more aggressive 
DLBCL. Our data showed that only one gene, 
MAP1LC3A, was up-regulated in DLBCL B-cells. It was 
recently reported that autophagy is positively regulated by 
LITAF which is silenced by promoter hypermethylation 
in germinal center-derived B-cell lymphomas, suggesting 
that autophagy may be inhibited in these lymphomas 
[38]. We found that levels of p62 and LC3 proteins 
showed a heterogeneous expression pattern in DLBCL 
and had no significant difference compared with RA 
controls. In addition, expression levels of p62 and LC3 
did not show association with clinical outcomes of 
patients with FL (data not shown). This suggests that up-
regulated autophagy in FL may not be associated with 
transformation to DLBCL. Instead, active autophagy in 
FL may even suppress tumor progression by eliminating 
damaged organelles and controlling genetic instability. 
Increased expression of autophagy-related genes 
was more readily detected in FL bulk tissue biopsies. 
Similar to FL purified B-cells, FL unpurified tissue also 
showed up-regulation of autophagy machinery genes, 
including ATG16L1, MAP1LC3A, ATG9, LAMP1 and 
HDAC6; many other autophagy machinery and regulatory 
genes were also significantly up-regulated. Among the 
up-regulated autophagy regulatory genes, TP53, MAPK8, 
HDAC1, DAPK1, CDKN1B, CDKN2A, UVRAG, and 
RPS6KB1 are positive regulators of autophagy, whereas 
AKT1, PIK3CG, BCL-2, BCL-2L1, mTOR, EIF4G1, 
and MAPK14 are negative autophagy regulators. It is 
obvious that more aberrantly expressed autophagy-
related genes were detected in unpurified FL samples 
compared with purified B-cells. Our previous studies 
show that FL tissues have increased numbers of CD163+ 
infiltrating macrophages [39] and CD4+ T-cells [40] in the 
microenvironment. This suggests that autophagy activity 
might also be altered in FL tumor infiltrating cells and 
this is being actively explored. Notably, we did not find 
evidence of upregulation of autophagy related genes in our 
previous studies of GEP of the tumor infiltrating T-cells 
in FL [31].
Fewer autophagy-related genes had altered 
expression levels in DLBCL, regardless of sample 
purification. Significantly up-regulated genes in DLBCL 
samples included CTSD, DRAM1 and TGM2. CTSD 
and DRAM1 are lysosomal proteins which regulate the 
autophagic flux through the lysosome [30, 41], while 
TGM2 is involved in autophagy-dependent clearance 
of ubiquitinated proteins [42]. We therefore tested the 
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origin of cells expressing high levels of cathepsin D and 
TGM2 using TMAs. Expression of both cathepsin D and 
TGM2 proteins was significantly lower in FL samples but 
significantly higher in DLBCL samples compared with RA 
controls. Morphological features of cells expressing higher 
cathepsin D or TGM2 were identical to CD68-expressing 
TAMs. Indeed, expression levels of both cathepsin D 
and TGM2 were strongly correlated to CD68 expression 
levels in DLBCL. We found that increased cathepsin D 
expression was associated with a shorter overall survival 
of DLBCL patients (data not shown), in agreement with 
a previous report by Nicotra et al [43]. TGM2 has been 
reported as a marker for progression and therapeutic 
intervention in colorectal cancer and non-small cell lung 
cancer.[44, 45] However, the role of TGM2 in DLBCL 
is unknown. We found that TGM2 expression is not 
associated with shorter overall survival or other prognostic 
markers in DLBCL (data not shown). Nevertheless, 
CTSD and TGM2 expression levels in DLBCL did not 
reflect their expression in malignant B-cells. We therefore 
propose that determination of autophagy-related gene 
expression using unpurified lymphoma specimens could 
be distorted by high lysosome-containing TAMs. 
In summary, the role of BCL-2 in autophagy 
is currently elusive. Using the RT2 Profiler Human 
Autophagy PCR array and TMAs, we demonstrate 
that basal autophagy activity was up-regulated in 
primary BCL-2 overexpressing FL B-cells and their 
microenviromental cells. A greater number of autophagy 
machinery genes were up-regulated in the BCL-2+ DLBCL 
cell line Su-DHL4 at the basal level and in response to 
stress, indicating that overexpression of BCL-2 does not 
inhibit the autophagic flux. Instead, inhibition of apoptosis 
by overexpression of BCL-2 may switch on autophagy 
in the cell in favor of eliminating aged organelles and 
damaged proteins. However, the mechanism by which FL 
cells up-regulate autophagy-related gene expression is not 
clear and may be due to multiple factors. We therefore 
propose that overexpression of the anti-apoptotic protein 
BCL-2 does not suppress autophagy activity in human FL. 
MATERIALS AND METHODS
Cell lines and cell culture
Human DLBCL cell lines Su-DHL4 (BCL-2+) and 
Su-DHL8 (BCL-2-) [46] were used in this study. Cells 
were cultured in RPMI-1640 medium supplemented 
with 10% heat-inactivated fetal calf serum (FCS), 25mM 
HEPES, and 2.0mM L-glutamine at 37°C in a 5% CO2 
humidified incubator. To induce autophagy, cells were 
cultured in HBSS for up to 6 hours.
Human samples and ethical considerations
Ethical approval for the human biological materials 
used in this study was obtained in accordance with the 
requirements of the East London and the City Health 
Authority Local Research Ethics Committee (Ref. No. 
10/H0704/65). All samples were obtained from patients 
by informed consent. Patients selected presented at St. 
Bartholomew’s hospital between the years 1970-2012. 
For RT2 Profiler PCR array analysis, lymph node (LN) 
biopsies and cryopreserved single cell suspensions were 
obtained from diagnostic, previously un-treated FL (n=13) 
and DLBCL (n=11) patients (Suppl Table 1 and 2); RA-
LNs (n=11) were used as controls. For tissue microarrays 
(TMAs), LN biopsies from 128 FL and 144 DLBCL 
patients at diagnosis for whom quality formalin fixed 
paraffin embedded tissue, clinical and follow-up data 
were available, as well as 28 reactive LN biopsies, were 
included on the TMAs (Suppl Table 3 and 4). 
Reagents 
RT2 Profiler Human Autophagy PCR Array 
(PAHS084ZE), RNeasy mini kit, RT2 First Strand 
Kit, primers for qPCR validation, including BECN 
(PPH05670B), MAP1LC3A (PPH19436A), ATG4B 
(PPH15916A), DRAM1 (PPH19768F), CTSD 
(PPH00112F) and RPLPO (PPH21138F) were purchased 
from Qiagen-Sabiosciences. 3,3’-diaminobenzidine 
(DAB) was from BioGenex. TRIzol® reagent, 4-12% 
NuPAGE gels and Hanks balanced salt solution (HBSS) 
were from Invitrogen. Chloroquine (CQ), 4’,6-diamidino-
2-phenylindole (DAPI), and all other chemicals used were 
from Sigma. Antibodies used in this study are listed in 
Suppl Table 5.
Purification of B-cells by flow cytometry sorting
Primary single cell suspensions (106cells/ml) were 
washed once with washing buffer containing 2% FCS in 
PBS (phosphate buffered saline). Non-specific bindings 
were blocked by incubating cells with 2% human anti-γ-
globulin antibody for 30 min at 4°C. Cells were stained 
with conjugated anti-CD3/anti-CD20 or anti-CD3/
anti-CD19/anti-CD10 antibodies for 30 min at 4°C and 
subsequently washed once with washing buffer. Cells were 
resuspended in blocking buffer containing DAPI (50ng/
ml) and sorted on a BD FACSAria II Cell Sorter. DAPI 
was used to discriminate live and dead cells. Following 
selection of DAPI negative cells, T-cells were excluded by 
gating on CD3 negative (CD3-) cells. B-cells were isolated 
from the DAPI-/CD3- population based on expression 
of B-cell markers. DLBCL and reactive B-cells were 
identified by CD20 expression while FL B-cells were 
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isolated based on dual expression of CD19 and CD10. 
FL B-cells were further confirmed as the malignant cell 
population by demonstrating kappa/lambda (κ/λ) light 
chain restriction [47].
RNA extraction and cDNA conversion
Total RNA was isolated from purified single B-cell 
suspensions or solid LN tissue biopsies with TRIzol® and/
or the RNeasy mini kit. RNA quality was assessed using 
the Agilent 2100 Bioanalyzer (Agilent Technologies) and 
a Nanodrop spectrophotometer (Thermo-Scientific); all 
samples had an RNA integrity number (RIN) greater than 
6 and 260/280 ratios higher than 1.9. RNA (300ng) was 
converted to cDNA by RT-PCR using the RT2 First Strand 
Kit. 
RT2 Profiler PCR array for detection of 
expression of autophagy related genes
The RT2 Profiler PCR Array combines qRT-
PCR technology with a microarray format to allow the 
simultaneous detection of multiple gene expression levels 
in a rapid manner. The RT2 Profiler Human Autophagy 
PCR Array contains primers against 84 genes involved in 
different stages of the autophagy pathway (Suppl Table 
6 and 7) as well as primers against five housekeeping 
genes which are used for data normalization. According 
to the manufacturer’s protocol, qRT-PCR was performed 
by adding 2.8ng cDNA mixed with RT2 SYBR Green 
Mastermix (Sabiosiciences) to each well which already 
contained primers directed against the gene of interest. 
mRNA levels were analyzed using the ABI Prism 7900HT 
Fast Real-Time PCR System (Applied Biosystems) and a 
dissociation curve analysis step included to verify PCR 
specificity. Relative quantity (RQ) values were calculated 
using the formula RQ = 2-∆∆CT. Target cycle threshold (CT) 
values were normalized to the housekeeping gene RPLPO 
generating a ∆CT value. The average ∆CT of reactive 
controls was used as the calibrator sample on a per gene 
basis and was subtracted from each ∆CT generating a delta 
∆CT value which was linearized by raising to the power of 
2 (2-∆∆CT). Genes with a fold change ≥3 or ≤-3 or a FC ≥2 
or ≤-2 and a p value <0.05 using a Mann-Whitney U test 
or student t-test were taken to be biologically meaningful. 
Hierarchical clustering was performed using Euclidean 
distance measure and an average agglomeration available 
within the R statistical computing environment. 
qRT-PCR validation 
Following conversion of RNA (500ng) to cDNA, 
samples were prepared for qRT-PCR as previously 
described and the qRT-PCR assay run under the previously 
stipulated conditions. All genes validated, including the 
housekeeping gene RPLPO, were analyzed in triplicate 
and a no-template control (NTC) also included per gene. 
Primers used in validation experiments were identical to 
those present on the RT2 Profiler Human Autophagy PCR 
Array. 
Tissue microarray (TMAs) and IHC analysis
TMAs were constructed using a semi-automated 
arraying system (TMABooster-Alphelys). Sections of 
biopsy material were stained with hemotoxylin and eosin 
and reviewed by an expert histopathologist (C.M.) who 
identified areas rich in malignant cells. Triplicate 1mm2 
cores were then taken from these areas, arrayed and 
stained as previously described [31, 33, 34]. Slides were 
digitalized and image analysis was performed using a 
digital pathology system (Ariol, Lieca Microsystems). 
The Ariol image analysis classifier was trained based on 
the hue, saturation and intensity of DAB staining, such 
that only areas stained above a pre-determined threshold 
representing the highest intensity staining were classed 
as positive, and lower level background expression was 
excluded. A further classifier was used to determine the 
total viable tissue area. Combining these two classifiers, 
the percent stained area was calculated. In FL cores, 
intra-follicular areas were selected based on expression 
of CD10 and clear follicle morphology. Results were 
manually and blindly reviewed and reported as an average 
of the triplicate cores. Protein levels were expressed as % 
stained area [33]. 
Western blotting
Proteins were extracted with lysis buffer and 50 µg 
of proteins added to each lane of 4-12% NuPAGE gels and 
Western blotting was performed as previously described 
[33].
Statistical analysis 
Statistical analysis was performed using GraphPad 
Prism software (version 5.03). Data are shown as either 
mean ± SD or median with interquartile range when 
variation was high. Significant differences between groups 
with unequal size were analyzed with the Mann-Whitney 
U test and those with equal size were analyzed using the 
student t-test. Pearson product-moment correlation method 
was used to analyze linear correlation between two groups. 
All P-values less than 0.05 were considered statistically 
significant. 
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